尿液可溶性CD163与IgA肾病免疫抑制治疗反应及肾脏复发的关系
这项前瞻性队列研究纳入281例高进展风险的IgA肾病患者,均接受中位18个月的免疫抑制治疗。基线尿sCD163最高三分位组治疗反应 odds 是最低三分位组的8.04倍(95%CI 3.88-16.67),加入尿sCD163后临床-病理模型AUC提升至0.82;纵向尿sCD163与复发时间显著相关(调整HR 1.38,95%CI 1.21-1.56)。
要点
- 基线尿sCD163与肾活检CD163阳性巨噬细胞密度强相关。
- 基线尿sCD163最高三分位组治疗反应 odds 为最低三分位组的8.04倍。
- 纵向尿sCD163与复发时间独立相关(调整HR 1.38)。
核心结论
- 尿sCD163独立与免疫抑制治疗反应相关,并可能作为高危IgA肾病患者 impending 复发的生物标志物。
研究设计与样本
- 前瞻性队列研究,纳入281例高进展风险IgA肾病患者,均接受中位18个月的免疫抑制治疗。
主要发现
- 基线尿sCD163与肾活检肾小球及小管间质CD163阳性巨噬细胞密度强相关。
- 基线尿sCD163最高三分位组治疗反应 odds 为最低三分位组的8.04倍(调整OR 8.04,95%CI 3.88-16.67)。
- 将尿sCD163加入临床-病理模型显著提高对治疗反应的区分能力,AUC升至0.82。
- 纵向尿sCD163与复发时间显著相关(调整HR 1.38,95%CI 1.21-1.56)。
关键数值与推荐
- 治疗反应定义为免疫抑制12个月内尿蛋白排泄减少且肾功能稳定。
- 复发定义为缓解后尿蛋白排泄增加。
临床怎么用
- 在高危IgA肾病患者中,可考虑检测基线及纵向尿sCD163辅助评估免疫抑制治疗反应与复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The absence of a dynamic, noninvasive biomarker to monitor intrarenal immunologic activity during and after immunosuppressive therapy limits patient-specific risk stratification and timely treatment decisions in IgA nephropathy (IgAN). The clinical utility of urinary soluble CD163 (sCD163) for predicting response to immunosuppressive therapy and detecting renal relapse remains to be fully elucidated. METHODS: This prospective cohort study included 281 patients with IgAN who were at high risk of progression. All the patients received immunosuppressive therapy for a median of 18 months. Urinary sCD163 levels were measured and normalized to creatinine. Treatment response to immunosuppression was defined as a reduction in urinary protein excretion with stable renal function within 12 months of immunosuppression. Relapse was defined as an increase in urinary protein excretion after remission. RESULTS: Baseline urinary sCD163 correlated strongly with glomerular and tubulointerstitial CD163-positive macrophage density on kidney biopsy. Patients in the highest tertile of baseline urinary sCD163 had 8-fold greater odds of treatment response (adjusted odds ratio: 8.04, 95% confidence interval [CI]: 3.88-16.67) than those in the lowest tertile. Adding urinary sCD163 to a clinical-histological model significantly improved the discriminatory ability for treatment response, increasing the area under the receiver operating characteristic curve (AUC) to 0.82. Longitudinal urinary sCD163 was significantly associated with time to relapse, with an adjusted hazard ratio of 1.38 (95% CI: 1.21-1.56). CONCLUSION: Urinary sCD163 is independently associated with response to immunosuppressive therapy and may serve as a potential biomarker for impending relapse in high-risk IgAN, which could help personalize therapeutic management.
引用
- Zhao H, Zhan Z, Lin T, et al. Association of Urinary Soluble CD163 With Response to Immunosuppressive Therapy and Renal Relapse in IgAN. Kidney Int Rep. 2026. PMID: 42254851. doi:10.1016/j.ekir.2026.106586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。